<DOC>
	<DOCNO>NCT00982631</DOCNO>
	<brief_summary>A study examine combination temsirolimus Caelyx® ( chemotherapeutic ) advance recurrent breast , endometrial ovarian cancer .</brief_summary>
	<brief_title>A Study Combination Temsirolimus ( Torisel® ) Pegylated Liposomal Doxorubicin ( PLD , Doxil®/Caelyx® ) Advanced Recurrent Breast , Endometrial Ovarian Cancer</brief_title>
	<detailed_description>To assess maximum tolerate dose ( MTD ) recommend phase II dose combination temsirolimus Caelyx® patient advance therapy refractory breast cancer , endometrial cancer , ovarian cancer .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients proven advance breast cancer , endometrial cancer ovarian cancer , refractory standard therapy standard therapy exists . Age ≥ 18 year Patients ECOG status 0 1 Patients life expectancy least 12 week Negative pregnancy test female patient childbearing potential Signed inform consent Adequate bone marrow : neutrophil ≥ 1.5 x 109/L , platelet ≥ 100 x 109/L haemoglobin ≥ 5.0 mmol/l Adequate renal function : GFR ≥ 60 ml/min Adequate liver function : ALT AST &lt; 2.5 x ULN , total bilirubin ≤ 1x ULN Fasting level total cholesterol 350 mg/dL ( 9.1 mmol/L ) triglyceride level 400 mg/L ( 4.5 mmol/L ) Left ventricular ejection fraction ( LVEF ) &lt; 50 % History serious cardiac disease Active clinically serious bacterial , viral fungal infection ( &gt; grade 2 ) . Known history human immunodeficiency virus ( HIV ) infection chronic hepatitis B C. Clinically symptomatic brain meningeal metastasis . Patients seizure disorder require medication ( steroids antiepileptic ) . Concomitant treatment strong CYP3A4 inductor ( rifampicin , St. John´s Wort ) CYP3A4 inhibitor ( ketoconazole , voriconazole , itraconazole , diltiazem , verapamil , erythromycin ) within 2 week prior start . Moderate weak CYP3A4 modifier use concomitantly careful assessment riskbenefit ratio . Concomitant use carbamazepine , phenobarbital , phenytoin chronic use dexamethasone allow . ( Table 1 ) Other concomitant anticancer therapy ( except steroid ) Concomitant use streptozocin , mercaptopurine . Previous treatment one study drug . Previous treatment mTOR inhibitor Prior investigational therapy/agents within 4 week start , case bevacizumab least 60 day bevacizumab discontinuation first dose temsirolimus . Surgical treatment radiation therapy past 4 week . Palliative radiotherapy focal site extremity allow , also within 4 week start Unresolved toxicity CTC ≥ grade 2 previous anticancer therapy except alopecia . Known suspected allergy investigational agent agent give association trial . Substance abuse , medical , psychological social condition may interfere patient participation study evaluation study result Any condition unstable could jeopardize safety patient compliance study . Antracyclines : &gt; 450 mg/m2 doxorubicin &gt; 600 mg/m2 epirubicin Medications know dysrhythmic potential permit ( ie , terfenadine , quinidine , procainamide , disopyramide , sotalol , probucol , bepridil , haloperidol , risperidone , indapamide ) Usage coumarinderivate anticoagulant . Low molecular weight heparin permit advise</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>temsirolimus ( Torisel® )</keyword>
	<keyword>pegylated liposomal doxorubicin ( PLD , Doxil®/ Caelyx® )</keyword>
</DOC>